Offer - Urjas Oil for just ₹ 1 X
Zynacar 800 Tablet is a commercial drug that is prescribed in the form of Tablet. Increased Phosphate Levels in the Blood are some of its major therapeutic uses. Zynacar 800 Tablet also has some secondary and off-label uses. These are listed below.
The optimal dosage of Zynacar 800 Tablet is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Zynacar 800 Tablet as well, which are listed below. These side effects of Zynacar 800 Tablet are usually temporary and subside with the completion of treatment. Consult your doctor if these side effects become worse or stay for a longer duration.
In addition, Zynacar 800 Tablet's effect is Unknown during pregnancy and Safe for lactating mothers. In addition, Zynacar 800 Tablet's effects on the liver, heart and kidney are discussed below in the Zynacar 800 Tablet related warnings section.
Zynacar 800 Tablet is not recommended if you suffer from certain medical conditions as it can have adverse effects. Intestinal Obstruction are examples of such conditions. The section on Zynacar 800 Tablet contraindications lists all such conditions.
Drug reaction of Zynacar 800 Tablet with other medicines has been reported. Refer to the list below for further details.
In addition to these precautions, you may also note that Zynacar 800 Tablet is safe while driving, and is is addictive in nature.
Zynacar 800 Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Is the use of Zynacar 800 Tablet safe for pregnant women?
The effects of Zynacar on pregnant women are unknown since no research has been done to ascertain it yet.
Is the use of Zynacar 800 Tablet safe during breastfeeding?
Zynacar is safe for breastfeeding women.
What is the effect of Zynacar 800 Tablet on the Kidneys?
Zynacar rarely affects the kidneys.
What is the effect of Zynacar 800 Tablet on the Liver?
So far, no research has been carried out on the effects of Zynacar on the liver. So it is not known whether taking Zynacar will affect the liver or not.
What is the effect of Zynacar 800 Tablet on the Heart?
No research work has been carried out till date on effects of Zynacar on heart. So it is not known whether taking Zynacar will cause side effects on heart or not.
If you are suffering from any of the following diseases, you should not take Zynacar 800 Tablet unless your doctor advises you to do so -
Is this Zynacar 800 Tablet habit forming or addictive?
No, there is no any evidence that Zynacar 800 Tablet is addictive.
Is it safe to drive or operate heavy machinery when consuming?
Zynacar 800 Tablet does not cause dizziness or sleep, so you can drive a vehicle or operate machinery also.
Is it safe?
Yes, Zynacar 800 Tablet is safe but you must consult your doctor before taking it.
Is it able to treat mental disorders?
Zynacar 800 Tablet is unable to treat or cure mental disorders.
Interaction between Food and Zynacar 800 Tablet
Due to the absence of research, it is difficult to say how Zynacar 800 Tablet and food will interact.
Interaction between Alcohol and Zynacar 800 Tablet
No research has been done on this till date. Therefore, it is not known what the effect of taking Zynacar 800 Tablet with alcohol will be.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Renvela (sevelamer carbonate)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1134-1135